Lung cancer diagnosis on virtual histologically stained tissue using weakly supervised learning.

Researchers

Journal

Modalities

Models

Abstract

Lung adenocarcinoma (LUAD) is the most common primary lung cancer and accounts for 40% of all lung cancer cases. The current gold standard for lung cancer analysis is based on the pathologists’ interpretation of hematoxylin and eosin (H&E)-stained tissue slices viewed under a brightfield microscope or digital slide scanner. Computational pathology using deep learning has been proposed to detect lung cancer on histology images. However, the histological staining workflow to acquire the H&E-stained images and the subsequent cancer diagnosis procedures are labor-intensive and time-consuming with tedious sample preparation steps and repetitive manual interpretation, respectively. In this work, we propose a weakly supervised learning method for LUAD classification on label-free tissue slices with virtual histological staining. The autofluorescence images of label-free tissue with histopathological information can be converted into virtual H&E-stained images by a weakly supervised deep generative model. For the downstream LUAD classification task, we trained the attention-based multiple instance learning (MIL) model with different settings on the open-source LUAD H&E whole-slide images (WSIs) dataset from the Cancer Genome Atlas (TCGA). The model is validated on the 150 H&E WSIs collected from patients in Queen Mary Hospital and Prince of Wales Hospital with an average area under the curve (AUC) of 0.961. The model also achieved an average AUC of 0.973 on 58 virtual H&E WSIs, comparable to the results on 58 standard H&E WSIs with an average AUC of 0.977. The attention heatmaps of virtual H&E and ground truth H&E can indicate tumor regions of LUAD tissue slices. In conclusion, the proposed diagnostic workflow on virtual H&E of label-free tissue is a rapid, cost-effective, and interpretable approach to assist clinicians in postoperative pathological examinations. The method could serve as a blueprint for other label-free imaging modalities and disease contexts.Copyright © 2024. Published by Elsevier Inc.